Autopsy report · NCT02551055

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

“Business Decision; No Safety Or Efficacy Concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 4 months before it stopped.
• 32 participants enrolled.
• Results were posted on the registry 2 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Millennium Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

Interventions

MLN1117; TAK-659; Alisertib; Paclitaxel; Docetaxel

Participants

32

Sites

6

Countries

Spain, United States

Trials that died the same way

• Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
  “Business Decision; No Safety Or Efficacy Concerns. (See below)” (95% match in meaning)
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
  “Business decision, insufficient enrollment, no safety or efficacy concerns.” (84% match in meaning)
• A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
  “This was a strategic business decision. There were no safety concerns contributing to this decision.” (79% match in meaning)
• Study of Poziotinib in Japanese Patients With NSCLC
  “Business decision, not related to safety.” (78% match in meaning)
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
  “Company decision not related to any safety concerns.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.